In a recent publication, Prof. Ki-Bum Lee and his research team (https://kblee.rutgers.edu/) collaborated with Prof. Mi-Hyeon Jang (Rutgers University, https://molbiosci.rutgers.edu/faculty-research/faculty/faculty-detail/83-i-j/984-jang-mi-hyeon) to review upcoming nanotechnology-based approaches to target neurotoxicity, neuropathy, and cardiomyopathy, three critical side effects of chemotherapy treatment [Figure 1].
Nanomaterials can have a variety of intrinsic therapeutic properties depending on their composition, shape, and size, such as anti-oxidant properties, neuroprotective effects, and cell-specific targeting. Nanomaterials can also be utilized for the selective delivery of therapeutics for either the treatment of off-target effects induced by chemotherapeutics or to selectivity deliver chemotherapeutics and prevent off-target effects from occurring. Both strategies are imperative to provide treatments for the millions of breast and ovarian cancer survivors, and for those living with cancer, as it leads to a better quality of life and provides relief from critical chemotherapeutic side effects. Overall, this review article provides insight into the current direction of nanotechnology to treat and prevent chemotherapeutic-induced diseases, as well as highlights the significant need for further research into this field to improve the lives of many cancer survivors.
PUBLICATION: This work was recently published in Small (https://doi.org/10.1002/smll.202300744). “Nanotechnology Approaches for Prevention and Treatment of Chemotherapy-Induced Neurotoxicity, Neuropathy, and Cardiomyopathy in Breast and Ovarian Cancer Survivors”, Small 2023, 2300744, DOI:10.1002/smll.202300744.
CORRESPONDENCE: Prof. Ki-Bum Lee (Rutgers University), https://kblee.rutgers.edu/
Collaborator: Dr. Mi-Hyeon Jang (Rutgers University, Robert Wood Johnson Medical School)
KBLEE Group Team: Sarah Nevins, Callan D. McLoughlin, Joshua B. Stein, Yannan Hou https://kblee.rutgers.edu/
